WO2001089448A3 - Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects - Google Patents

Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects Download PDF

Info

Publication number
WO2001089448A3
WO2001089448A3 PCT/IB2001/000758 IB0100758W WO0189448A3 WO 2001089448 A3 WO2001089448 A3 WO 2001089448A3 IB 0100758 W IB0100758 W IB 0100758W WO 0189448 A3 WO0189448 A3 WO 0189448A3
Authority
WO
WIPO (PCT)
Prior art keywords
drugs
pain
relief
side effects
adrenergic agonist
Prior art date
Application number
PCT/IB2001/000758
Other languages
French (fr)
Other versions
WO2001089448A2 (en
Inventor
John W Olney
Nuri B Farber
Vesna Jevtovic-Todorovic
Original Assignee
John W Olney
Nuri B Farber
Vesna Jevtovic-Todorovic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John W Olney, Nuri B Farber, Vesna Jevtovic-Todorovic filed Critical John W Olney
Priority to AU75765/01A priority Critical patent/AU7576501A/en
Publication of WO2001089448A2 publication Critical patent/WO2001089448A2/en
Publication of WO2001089448A3 publication Critical patent/WO2001089448A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A combination of two drugs, from different and unrelated categories, provides effective and long-lasting relief from neuropathic pain and other chronic or intractable pain. Both drugs can be taken in a painless non-invasive manner, such as by means of pills or skin patches. One drug is an α2 adrenergic agonist, exemplified by clonidine. These agents reduce blood pressure and have sedative-hypnotic effects; those are unwanted side effects in a chronic daily treatment for pain. The other drug is an NMDA antagonist which can be described as mild, minimally toxic, and/or inherently safe (or safened). Three such classes of drugs have been shown to work exceptionally well, with clonidine, in reducing neuropathic pain for prolonged periods: (1) aryl-cyclo-alkanolamine drugs such as procyclidine and biperiden; (2) tricyclo-alkylamine drugs such as ethopropazine; and (3) adamantane derivatives such as memantine. None of these drugs, by itself, can provide effective relief for neuropathic pain; at doses required to provide short-term relief, they cause adverse side effects, and any pain relief they provide is relatively brief. However, when combined with an α2 adrenergic agonist, the two drugs potentiate one another's pain-relieving action, and provide potent and sustained relief, even when each drug is administered at a low dosage that is below its threshold for causing adverse side effects.
PCT/IB2001/000758 2000-03-28 2001-03-28 Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects WO2001089448A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU75765/01A AU7576501A (en) 2000-03-28 2001-03-28 Combination of adrenergic agonist and nmda antagonist for relieving chronic painwithout adverse side effects

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53688900A 2000-03-28 2000-03-28
US53688800A 2000-03-28 2000-03-28
US09/536,889 2000-03-28
US09/536,888 2000-03-28

Publications (2)

Publication Number Publication Date
WO2001089448A2 WO2001089448A2 (en) 2001-11-29
WO2001089448A3 true WO2001089448A3 (en) 2002-08-15

Family

ID=27065300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000758 WO2001089448A2 (en) 2000-03-28 2001-03-28 Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects

Country Status (2)

Country Link
AU (1) AU7576501A (en)
WO (1) WO2001089448A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251993A1 (en) * 2002-07-19 2004-02-09 Inge Grundke-Iqbal NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2005034998A2 (en) * 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20080020076A1 (en) * 2006-07-21 2008-01-24 Khem Jhamandas Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists
CN102223791A (en) 2008-09-27 2011-10-19 塔阿克斯有限公司 Topical formulations for treatment of neuropathy
EP3054932B1 (en) 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
EP3054930B1 (en) 2013-10-07 2020-12-02 Teikoku Pharma USA, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
TWI629066B (en) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
CN110337289A (en) * 2016-12-29 2019-10-15 Rvx疗法有限公司 For enhance CNS drug and mitigate they side effect method and composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833138A (en) * 1987-10-23 1989-05-23 Washington University Phenothiazinealkaneamines for treatment of neurotoxic injury
US5502049A (en) * 1992-03-30 1996-03-26 Rhone-Poulenc Rorer S.A. Use of phenothiazine derivatives in the treatment of ischaemia and/or hypoxia
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5925634A (en) * 1989-10-20 1999-07-20 Washington University Use of ibogaine for treating neuropathic pain
US5980927A (en) * 1995-02-10 1999-11-09 Medtronic, Inc. Method and apparatus for administering analgesics, and method for making same device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833138A (en) * 1987-10-23 1989-05-23 Washington University Phenothiazinealkaneamines for treatment of neurotoxic injury
US5925634A (en) * 1989-10-20 1999-07-20 Washington University Use of ibogaine for treating neuropathic pain
US5502049A (en) * 1992-03-30 1996-03-26 Rhone-Poulenc Rorer S.A. Use of phenothiazine derivatives in the treatment of ischaemia and/or hypoxia
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5980927A (en) * 1995-02-10 1999-11-09 Medtronic, Inc. Method and apparatus for administering analgesics, and method for making same device

Also Published As

Publication number Publication date
WO2001089448A2 (en) 2001-11-29
AU7576501A (en) 2001-12-03

Similar Documents

Publication Publication Date Title
HK1088547A1 (en) Once daily dosage forms of trospium trospium
AU1877992A (en) Linsidomin for treating erectile dysfunctions
WO2004056305A3 (en) Administration of capsaicinoids
IT1261849B (en) MEDICAL DEVICE FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS OR VERY LOW DOSAGE DRUGS, IN PARTICULAR HOMEOPATHIC DRUGS.
CA2025078A1 (en) External Analgesic lotion and Method of Making
CA2446741A1 (en) Ophthalmic drug delivery device
CA2046014A1 (en) Reduction or prevention of skin irritation by drugs
EP2056825B1 (en) Use of opioid formulations in needle-less drug delivery devices
CA2454976A1 (en) Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient
WO2001089448A3 (en) Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects
CA2215692A1 (en) Method of modulating microcirculation
WO2004050025A3 (en) Combination of ibuprofen and oxycodone for acute pain relief
US20030054030A1 (en) Method and compositions for the treatment of pruritus
James Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
EP0693479A4 (en) Novel aconitine-like compound and antipyretic analgesic anti-inflammatory agent
WO1997046221A1 (en) Cosmetic method for treating and preventing the signs of skin ageing
EP0755685A4 (en) Medicinal composition for treating tardive dyskinesia and utilization thereof
Norton A tissue pressure model for palpatory perception of the cranial rhythmic impulse
ES2182840T3 (en) FACTOR XIII FOR THE TREATMENT OF SKIN WOUNDS.
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
WO1998034618A1 (en) Composition for use as a fungistat and for the treatment of fungal infections
WO2000043014A8 (en) Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
MOMMA et al. Acute oral toxicity and ocular irritation of chemicals in bleaching agents
Padma-Nathan Intracavernosal pharmacotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP